Older chronic lymphocytic leukemia patients have poor outcomes with standard treatments and are underrepresented in clinical trials. We retrospectively reviewed outcomes of refractory chronic lymphocytic leukemia patients in two age categories (≥70 and <70 years) treated with single-agent flavopiridol, a drug active in genomically high-risk patients, during two trials. No significant difference...

As a means of identifying damage recognition proteins involved in repair of nitrogen mustard lesions in chronic lymphocytic leukemia, we performed Southwestern analysis using a probe damaged with melphalan and protein extracts from chronic lymphocytic leukemia patients. We detected proteins with molecular weights of 116,000, 66,000, and 64,000 which bound the damaged probe with a higher specifi...

Erythrocytes coated with varying amounts of human complement were used to detect lymphocytes with complement receptors from normal subjects and patients with chronic lymphocytic leukemia. The relationship between the percentage of lymphocytes rosetting and the quantity of C3 present on complement-coated erythrocytes were studied. Small quantities of C3 (less than 5 fg/erythrocyte) caused maxima...

small cell carcinoma of the urinary bladder (sccub) is an extremely rare bladder malignancy characterized by an aggressive clinical behavior. so, it is important to diagnose this high grade disease by urinary cytology. we report a case of sccub in an old man with chronic lymphocytic leukemia (cll) in remission, while bladder tumor was diagnosed by cytology. with this article, we aimed to review...

T HE SENSITIVITY OF LYMPHOCYTES to irradiation provides a rationale for the use of extracorporeal irradiation (ECI ) of the circulating blood to destroy lymphocytes selectively. Since 1962, ECI has been used in various studies, including investigations of lymphocyte physiology and prolongation of allogeneic skin graft survival in calves. These studies1 established the basic feasibility and effe...

TRial SUMMaRy: RESONaTETM-17: interim results for ibrutinib in Cll with 17p deletion O’brien s, Jones J, coutre s, et al. efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II resONateTM-17 trial, american society of Hematology annual meeting, december 8, 2014, session 642....

Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

BACKGROUND Morphology and cytochemistry are the foundation for classification of leukemias in dogs and cats. Advances in automated hematology instrumentation, immunophenotyping, cytogenetics, and molecular biology are significantly improving our ability to recognize and classify spontaneous myeloproliferative and lymphoproliferative disorders. OBJECTIVE The purpose of this study was to assess...

Environmental Health Perspectives • volume 119 | number 11 | November 2011 A 469 and does not alter our conclusion that this meta-analysis provides support for an association between occupational exposure to benzene and increased risk of multiple myeloma, acute lymphocytic leukemia, and chronic lymphocytic leukemia (Vlaanderen et al. 2011). The authors declare they have no actual or potential c...

The Philadelphia chromosome is present in more than 95% of chronic myeloid leukemia patients and 13% of acute lymphocytic leukemia patients. The Philadelphia translocation, t(9;22), fuses the BCR and ABL genes resulting in the expression of leukemia-specific, chimeric BCR-ABL messenger RNAs. To facilitate diagnosis of these leukemias, we have developed a method of amplifying and detecting only ...